Compare Extra Space Storage, Inc. (EXR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Extra Space Storage, Inc. trades at $133.62 (market cap $28.26B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Extra Space Storage, Inc. is far larger — about 5.8× Travere Therapeutics Inc. Common Stock's market cap, and Extra Space Storage, Inc. pays a 4.85% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 109 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EXR | TVTX | |
|---|---|---|
Market Cap | $28.26B | $4.88B |
Volume | 1,443,466 | 1,668,577 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $67.52 |
52-Week Low | $126.67 | $26.79 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $41.97B | $5.01B |
Dividend Yield | 4.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $134.06, up slightly by 0.01% today, with a neutral technical signal and bearish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Revenue grew to $3.38 billion in 2025, and net income reached $974 million, supported by a robust gross margin of 70.78%. Analyst consensus is evenly split between Buy and Hold, with a price target of $158.33, suggesting potential upside. Recent news highlights leadership transitions and steady dividend payments.
Outlook: EXR shows solid operational performance and financial flexibility, but faces risks from high leverage and softer housing demand. The stock's valuation metrics like P/E of 29.52 and EV/EBITDA of 17.35 indicate premium pricing. Investment opportunity lies in sustained earnings growth and dividend yield, while risks include interest rate sensitivity and competitive pressures in the REIT sector.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
